Q3 EPS Estimate for Bio-Rad Laboratories Reduced by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research cut their Q3 2027 EPS estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the medical research company will post earnings per share of $2.39 for the quarter, down from their prior forecast of $2.94. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The company had revenue of $653.00 million for the quarter, compared to analyst estimates of $651.30 million. During the same quarter in the previous year, the company posted $2.01 EPS. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Several other analysts have also recently commented on the stock. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Royal Bank Of Canada upped their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Citigroup lifted their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Wednesday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Stock Up 4.4%

Shares of BIO stock opened at $316.92 on Friday. The stock’s 50-day simple moving average is $304.72 and its 200-day simple moving average is $272.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The firm has a market capitalization of $8.55 billion, a PE ratio of -13.04 and a beta of 1.04. Bio-Rad Laboratories has a fifty-two week low of $211.43 and a fifty-two week high of $373.69.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the transaction, the executive vice president owned 510 shares of the company’s stock, valued at approximately $156,151.80. The trade was a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.06% of the company’s stock.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the business. Quent Capital LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter worth about $25,000. Caitong International Asset Management Co. Ltd increased its position in shares of Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares in the last quarter. Quarry LP acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter worth approximately $29,000. Farther Finance Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after buying an additional 36 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in shares of Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.